Download Citation
Article Source:
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
Pannus P,
Depickère S,
Kemlin D,
Houben S,
Neven KY,
et al.
(2022)
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial.
PLOS Global Public Health 2(12): e0001308.
https://doi.org/10.1371/journal.pgph.0001308